We are international
• treatment options TEXT SIZE   
Clinical Trials


Kyprolis® (carfilzomib) was first approved by the FDA in 2012 for the treatment of patients with myeloma who have received at least two prior therapies, including the proteasome inhibitor Velcade® (bortezomib) and an immunomodulatory drug (IMiD®), Revlimid® (lenalidomide) or Thalomid® (thalidomide), and have demonstrated disease progression on or within 60 days of the completion of the last therapy.

On July, 24, 2015, the FDA approved Kyprolis given in combination with Revlimid® (lenalidomide) and dexamethasone to treat patients with relapsed multiple myeloma who have previously received at least one prior treatment.

On September 18, 2015, the FDA granted priority review of a supplemental new drug application to expand the indication for Kyprolis in combination with dexamethasone to include the treatment of patients who have received at least one prior therapy. The FDA will announce its decision on this application by January, 2016.

General Information
Clinical Trials
Blogs and Press Releases
ARROW Clinical Trial
Fact Sheet
A Randomized, Open-label, Phase III Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib (Kyprolis®) in Combination with Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study

Ola Landgren, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM)

Dr. Andrzej Jakubowiak
University of Chicago Medical Center
Chicago, Illinois,  USA

A Fact Sheet
Phase III Study with Carfilzomib & Dexamethasone vs Velcade & Dexamethasone for Relapsed MM Patients. Sites actively opening, so call the Hotline for the most up-to-date listings.

The ENDEAVOR TRIAL on clinicaltrials.gov
Open Carfilzomib Trials